Bcl-2 may play a role in the progression of endometrial hyperplasia and early carcinogenesis, but not linked to further tumorigenesis  by Laban, Mohamed et al.
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The  role  of Bcl-2  in initiation  and  progression  of endometrial  carcinoma  is  still  with  incon-
sistent results.  The  aim  of  this  study  is to determine  the role  of Bcl-2  in  endometrial
tumorigenesis.  It is  a retrospective  cross  sectional  study.  We  used  100  endometrial  parafﬁn
embedded  specimens  for  Bcl-2  oncoprotein  immunohistochemical  staining;  20  samples
of normal  endometrium,  40 specimens  of  endometrial  hyperplasia  (simple,  complex  and
atypical) and  40  specimens  of  endometrioid  adenocarcinoma.  The  results  were  statistically
analyzed.  There  was  a signiﬁcant  increase  in  Bcl-2  staining  from  normal  through  complex
and  atypical  hyperplasia  into  well  differentiated  adenocarcinoma  (P = 0.002,  P =  0.0008  and
P =  0.0001,  respectively).  There  was  a signiﬁcant  difference  between  the  staining  of different
types  of  endometrial  hyperplasia;  as  it up streamed  from  the  simple  through  the complex
up  to the  atypical  types  (P <  0.05).  Bcl-2  staining  showed  no  signiﬁcant  correlation  with
the  moderately,  poorly  differentiated  and  the different  stages  of  adenocarcinoma  (P  = 0.6,
P =  0.29  and  P = 0.1 respectively).
These results  might  indicate  a substantial  role for Bcl-2  as one  of the  initiating  drives  for
endometrial  tumorigenesis,  but  not  in further  tumor  progression.
© 2014  Saudi  Society  of  Microscopes.  Published  by  Elsevier  Ltd.  All  rights  reserved.. Introduction
Cancer of the uterine corpus is known to be the most
ommon malignancy seen in the female pelvis, and it is
wice  as common as carcinoma of the ovary and the cervix.
ndometrial carcinoma occurs during the reproductive and
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213-879X/© 2014 Saudi Society of Microscopes. Published by Elsevier Ltd. All rimenopausal years. The median age for adenocarcinoma
of the uterine corpus is 61 years with the largest num-
ber  of patients noted between 50 and 59 years. Multiple
risk factors for endometrial carcinoma have been identiﬁed
including; obesity, hypertension, diabetes mellitus, nulli-
parity,  late menopause and positive family history [1–3].
In  Egypt, uterine cancer is one of the most com-
mon  gynecological malignancies. It showed the highest
urban–rural incidence rate ratio, it also showed the high-
est  urban incidence among the oldest age group (70+ age
category) and in developed districts [4].
Apoptosis or programmed cell death is a well known
fundamental feature that provides an efﬁcient mechanism
ghts reserved.
scopy an20 M. Laban et al. / Journal of Micro
for eliminating cells, thus keeping cell numbers at constant
levels in different organs. The B cell leukemia, lymphoma-
2  gene (Bcl-2) was the ﬁrst gene identiﬁed that inhibits
apoptosis in many cell systems. This gene was ﬁrst detected
in  follicular and diffuse lymphomas, but the ﬁnding of Bcl-
2  expression in various epithelial tissues, such as breast,
cervix and ovary suggested a possible role for development
of  some epithelial neoplasms [5–9].
Bcl-2 family proteins are known to play a crucial role in
the  regulation of the cell proliferation, as Bcl-2/BAX ratio
keeps  the proliferation balance of the endometrial cells.
However, the deﬁnite role of this family in initiation, dif-
ferentiation and invasiveness has not been well understood
[10].
Cyclical variation in Bcl-2 expression in normal
endometrial glandular epithelium has been suggested [10].
As  Bcl-2 gene might increase the proliferative activity of
the  glandular endometrium [11], it might eventually lead
to  the development of endometrial hyperplasia and possi-
bly  neoplasia. The apoptotic mechanism has been shown
to  take place due to change in the expression of the gene
family  controlling the apoptosis [12–16].
Recently anti-Bcl-2 targeted therapy has been used in
several  tumors such as leukemia, small cell carcinoma of
the  lung, ovarian and breast cancers; thus the study of Bcl-2
expression in one of the most common gynecological dis-
eases  as endometrial hyperplasia and carcinoma becomes
increasingly attractive [17].
Several studies investigated the Bcl-2 expression in nor-
mal  and hyperplastic endometria as well as endometrial
adenocarcinoma; with inconsistent results. Some authors
showed increased Bcl-2 expression in endometrial carci-
noma  especially in low grade endometrioid type [10,18],
while  others showed decreased expression in endometrial
carcinoma [19–22].
The  aim of the present study was to investigate and
compare the expression of the Bcl-2 oncoprotein in nor-
mal  endometrium, and in cases of endometrial hyperplasia
and endometrial adenocarcinoma searching for a possible
role  for Bcl-2 in the development of endometrial adenocar-
cinoma.
2.  Materials and methods
2.1.  Specimens and data collection
This retrospective study was conducted at Ain Shams
University Specialized Hospital (ASUSH), Cairo, Egypt in the
duration  from March 2010 to March 2013.
The study included archival parafﬁn-embedded tis-
sue  specimens obtained from women following either
endometrial curettage (D&C) or hysterectomy.
The criteria for the selection of the specimens were; nor-
mal  endometrial specimens taken for endometrial dating in
patients  with infertility, endometrial hyperplasia (simple,
complex and atypical) and endometrial adenocarcinoma
(endometrioid type).We  tried to select the control group among women dur-
ing  the reproductive years of age as their endometrium is
exposed  to the normal hormonal effect that supposed to
have  a normal Bcl-2 expression. On the other hand, Bcl-2d Ultrastructure 3 (2015) 19–24
is  mainly expressed in proliferative endometrium under
estrogenic stimulation [23], while in postmenopausal
endometrium it is immunonegative or slightly positive to
Bcl-2  [24].
We  excluded specimens of patients with history of hor-
monal  treatment, anti-estrogen treatment, chemotherapy
or radiotherapy. Representative parafﬁn blocks and hema-
toxylin  and eosin (H&E)-stained sections were retrieved
from the pathology department at ASUSH, the rule of work
in  which is the consensus review of all the slides for conﬁr-
mation  of the diagnosis. The patients’ ﬁles were reviewed
to  record the patients’ age, weight, parity as well as the
treatment protocol and the surgical FIGO staging in patients
with  cancer [25]. For statistical purposes; stages III and IV
were  grouped together.
The  hospital Research & Ethical Committee approved
the study. Institutional review board determined a waiver
of  patients’ consent as data were collected and dealt with
in  an anonymous way.
2.2.  Immunohistochemical staining
Formalin ﬁxed, parafﬁn embedded tissue sections of
4  um thickness were immunostained for Bcl-2 mouse
monoclonal antibodies (clone 124; DAKO). The immuno-
histochemical technique was performed by applying the
supersensitive avidin–biotin detection kit (Biogenex, CA,
USA)  and following the technique of Hsu and Raine [26].
For  antigen retrieval, boiled water bath and sodium citrate
buffer  (pH 6.0) were used. To prevent the endogenous per-
oxidase  cross reaction, 3% H2O2 solution was  used. The
slides were incubated overnight with Bcl-2 antibodies at
room  temperature diluted 1:200. In parallel, positive con-
trols  (using normal human tonsil) and negative controls (by
omitting  the primary antibody) were performed to ensure
correct  staining procedure.
Bcl-2  oncoprotien expression was  examined and further
semi-quantitatively scored according to the intensity and
extent  of staining; (0) No immunostaining (1+) for weak
positive staining and (2+) for strong positive staining [27].
The  scoring was  done by two  independent pathologists
who  were unaware with the score results of each other.
2.3.  Statistical analysis
Patients’  characteristics were coded, entered, and
processed by using SPSS (version 11). Description of quan-
titative  variables was  done using mean, standard deviation
(SD),  and range. One-way Anova test (analysis of variance)
was  used to test the difference between the mean values of
the  demographic data among the different groups. Fisher’s
exact  test was used to compare the statistical difference
of Bcl-2 expression scores between different groups in
comparison to the normal endometrium. For statistical
purposes; we added the number of the weakly and strongly
positive cases together for each group. A p-value of 0.05 was
considered the cut-off value for signiﬁcance.Our choice of the sample size was based on calculation
by using STATA® version 11 programs, setting the type-1
error (˛) at 0.05 and the power (1 − ˇ) at 0.8. The cal-
culation was  based upon references which claimed that
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Table 1
Statistical correlation between the normal endometrium versus other groups with regard to immunohistochemical Bcl-2 staining.
Group (number of patients) Negative Bcl-2 (%) Positive Bcl-2 P
Weak (1+) (%) Strong (2+) (%)
Normal endometrium (20) 16 (80%) 4 (20%) 0
Endometrial hyperplasia (40)
Simple (12) 10 (83%) 1 (8.5%) 1 (8.5%) 1
Complex (16) 4 (25%) 6 (34.5%) 6 (34.5%) 0.002*
Atypical (12) 2 (17%) 2 (17%) 8 (66%) 0.0008**
Endometrial carcinoma (40)
Well differentiated (24) 4 (16.7%) 2 (8.3%) 18 (75%) 0.0001**
Moderately differentiated (10) 4 (40%) 2 (20%) 4 (40%) 0.06
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iPoorly differentiated (6) 3 (50%)
* P is signiﬁcant.
** P is highly signiﬁcant.
cl-2 expression in proliferative endometrium in about
0–100%, while in endometrial hyperplasia it is 25–80%
nd 60–70% in endometrial carcinoma, so to ﬁnd about 35%
ifference in expression of Bcl-2 between the control and
ither  hyperplasia or carcinoma group, we had to have 19
ontrol  specimens and 35 specimens for each hyperplasia
nd carcinoma [18,19].
.  Results
We  collected 109 specimens, nine of which had incom-
lete personal or surgical staging data, or had previous
ormonal therapy. The remaining 100 specimens were;
0  normal endometrium (6 at proliferative phase, 7 at
arly  secretory phase and 7 at late secretory phase), 40
ndometrial hyperplasia (12 simple, 16 complex and 12
typical),  and 40 endometrioid endometrial carcinoma (24
ell-differentiated [G1], 10 moderately [G2] and 6 poorly
ifferentiated [G3]).
The  demographic data of the patients revealed that age,
arity  and weight showed a signiﬁcant statistical difference
mong the different groups (P < 0.0001). The greatest val-
es  of age and weight were recorded among patients with
ndometrial adenocarcinoma.
Immunohistochemical staining of Bcl-2 in different
pecimens revealed weakly positive staining in only 4
ormal  endometrial biopsies (3 proliferative and 1 early
ecretory endometria). Staining of the endometrial hyper-
lasia  specimens revealed up-streaming positivity from
he  simple through the complex (P = 0.002) and up to the
typical  type (P = 0.0008) with signiﬁcant statistical dif-
erence  compared to the normal endometrium. The total
ositively stained specimens of the endometrial hyperpla-
ia  were 24 out of 40 specimens (60%); most of which
howed strong positive staining (Table 1, Fig. 1).
Staining results of the different grades of endome-
rial carcinoma showed statistical signiﬁcant differ-
nce between the normal endometrium and the well-
ifferentiated adenocarcinoma (P = 0.0001). There was  a
ownstream positivity from the well differentiated type
hrough  the moderately and down to the poorly differen-
iated adenocarcinoma but the difference was statistically
on-signiﬁcant (P = 0.29). The total positively stained spec-
mens  of endometrial carcinoma were 29 out of 403  (50%) 0  0.29
specimens (73%); most of which were G1 and showed
strong positive staining (Table 2, Fig. 1).There was no
statistical signiﬁcant correlation between the immunohis-
tochemical staining of Bcl-2 and the different tumor stages
(P  = 0.1) (Table 2).
4. Discussion
Several research studies investigated the correlation
between Bcl-2 in endometrial hyperplasia and adenocar-
cinoma in comparison to the normal endometrium with
inconsistent results regarding its role in endometrial car-
cinogenesis and differentiation [18–22].
This study showed a signiﬁcant difference in Bcl-2
expression between the normal endometrium and both
endometrial hyperplasia and carcinoma. There was a sub-
stantial  increase in Bcl-2 expression in specimens of the
complex and atypical hyperplasia as well as the well-
differentiated endometrial adenocarcinoma. On contrary,
the  poorly differentiated endometrial adenocarcinoma
showed decrease expression of Bcl-2.
Staining of endometrial hyperplasia and the adenocar-
cinoma (G1) specimens revealed up-streaming positivity
from  the simple through the complex as well as the
atypical type up to the well differentiated adenocar-
cinoma with signiﬁcant statistical difference. However,
this signiﬁcant difference was  lost when expression was
compared in specimens with moderately and poorly differ-
entiated  adenocarcinoma. This might suggest that patients
with  complex and atypical hyperplasia are more likely to
develop  endometrial carcinoma than those with simple
hyperplasia. Furthermore, it emphasized that Bcl-2 might
act  as an initiating impulse for carcinogenicity, afterwards,
the  aggressive biological behavior of the tumor would
depend on factors other than Bcl-2.
Bcl-2 did not show an important role in endometrial
cancer invasive capabilities, as there was no statistical cor-
relation  between the immunohistochemical expression of
Bcl-2  and the different stages of the endometrial cancer.
One  of the limitations of this study is its cross-sectional
design; longitudinal follow-up was not done to conﬁrm the
study  conclusion.
Strengths of the study were the fair size of the sam-
ple studied, the sample stratiﬁcation; as it included all
22 M. Laban et al. / Journal of Microscopy and Ultrastructure 3 (2015) 19–24
itivity. (
l-2 × 10
.Fig. 1. A; normal proliferative endometrial gland with focal weak Bcl-2 pos
are  Bcl-2 positive, they are embedded in scanty endometrial stroma (Bc
adenocarcinoma. Both show strong Bcl-2 staining positivity (Bcl-2 × 100)
types of endometrial hyperplasia and all grades and
stages of endometrial carcinoma. Furthermore, the semi-
quantitative assessment for Bcl-2 staining into weak and
strong  could give us more information about the strength
of  association between Bcl-2 and the different types of
endometrial pathology.
Our  study revealed expression of Bcl-2 staining in nor-
mal  endometrium (20%), endometrial hyperplasia (60%),
and  endometrial carcinoma (73%); the expression was
more  intense in the low grade compared to the high grade
carcinoma. This was in agreement with Mourizikou et al.
[10]  who showed that Bcl-2 expression was more frequent
Table 2
Statistical correlation between the different stages of the endometrial cancer and
expression.
Stage = number of patients
(%)
Number of patients with −ve
Bcl-2 expression (%)
Number
weak  Bc
Normal endometrium (20) 16 (80%) 4 (20%) 
I  = 26 (65%) 5 (19.2%) 1 (3.8%) 
II  = 7 (17.5%) 4 (57%) 2 (28.5%
III  and IV = 7 (17.5%) 2 (28.5%) 5 (71.5%
Total  = 40 11 (27.5%) 8 (20%) Bcl-2 × 200). B; complex endometrial hyperplasia, the endometrial glands
0). C; well differentiated adenocarcinoma, D; moderately differentiated
in  low-grade carcinoma and none in the high grade. Marone
et  al. [18] stated that Bcl-2 was expressed in neoplastic
endometrium more often than the normal counterpart.
There was  no statistical signiﬁcant correlation between
Bcl-2 expression and the tumor stage which was in accor-
dance  with the results of Erkanli et al. [19] in which Bcl-2
staining results in endometrial carcinoma were nearly
close to that of our study, they used biopsies of proli-
ferative endometrium as a control; the results of BCL-2
staining in which were 100% positive and that was  why
they  concluded that BCL-2 expression was  less in endome-
trial  carcinoma in comparison to the normal endometrium.
 the normal endometrium regarding the immunohistochemical of Bcl-2
 of patients with
l-2 expression (%)
Number of patients with
strong  Bcl-2 expression (%)
P
0 0.2
20 (77%)
) 1 (14.5%)
) 0
21 (52.5%)
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This study showed different results with other studies
hat revealed that apoptosis increased when progressing
rom normal endometrium to hyperplasia and further to
ancer.  Decreased expression of Bcl-2 and increased rate of
poptosis  in advanced malignancy might reﬂect the loss of
ellular  homeostasis and differentiation [20–22].
Progestins either orally administered or through
evonorgestrel-releasing intrauterine system were used for
onservative  management of young patients with endome-
rial  hyperplasia [28] and endometrial adenocarcinoma
29]. Also there was a decrease in glandular Bcl-2 expres-
ion  in cases of endometrial hyperplasia after 3 months
f  treatment with levonorgestrel-releasing intrauterine
ystem with a signiﬁcant increase of apoptosis [30]. Conse-
uently,  Bcl-2 may  be used as an independent prognostic
arker; addition of Bcl-2 staining as a routine inexpen-
ive histopathological marker may  be useful to identify
nd follow up the small category of patients with atypical
yperplasia who may  progress to endometrial adenocarci-
oma and in need for the conservative medical treatment
o  retain their fertility. The presence of Bcl-2 expression
n repeated D&C specimens from those patients might
ndicate the more probability of progression to adenocar-
inoma and it can also predict the response to progestins
herapy in those patients.
Longitudinal  studies are needed to prove the role of
cl-2  in the initiation of endometrial cancer; preferably by
omparing  the prognosis of two groups of patients with
typical hyperplasia and under conservative management;
ne with negative and the other with positive Bcl-2 expres-
ion.
In  conclusion; Bcl-2 expression showed signiﬁcant dif-
erence  in the normal endometrium compared to both
ndometrial hyperplasia and well-differentiated endome-
rial  adenocarcinoma. This might represent a key in
nderstanding the initiation of endometrial neoplasia and
erve  as a possible prognostic marker for patients under
onservative medical treatment for complex or atypical
ndometrial hyperplasia.
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